Low remission rates and high incidence of adverse events in a prospective VEXAS syndrome registry
Yohei Kirino,Ayaka Maeda,Tomoyuki Asano,Kiyoshi Migita,Yukiko Hidaka,Hiroaki Ida,Daisuke Kobayashi,Nobuhiro Oda,Ryo Rokutanda,Yuichiro Fujieda,Tatsuya Atsumi,Dai Kishida,Hiroshi Kobayashi,Motoaki Shiratsuchi,Toshimasa Shimizu,Atsushi Kawakami,Kazuki Tanaka,Tomohiro Tsuji,Koji Mishima,Takako Miyamae,Anna Hasegawa,Kei Ikeda,Tomoya Watanabe,Yukie Yamaguchi,Ryuta Nishikomori,Osamu Ohara,Hideaki Nakajima,,Yutaka Inaba,Kohei Tsujimoto,Ken Nagahata,Yuji Miyoshi,Yoichi Takeuchi,Kensaku Takatsuki
DOI: https://doi.org/10.1093/rheumatology/keae530
2024-09-28
Rheumatology
Abstract:Abstract Objective We aimed to gather real-world clinical evidence of detailed disease activity, treatments, remission rates, and adverse events (AEs) associated with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome in a prospective study. Methods Patients in Japan suspected of having VEXAS syndrome were enrolled in a registry study. A novel disease activity measure (VEXASCAF) assessing 11 symptoms associated with VEXAS syndrome was evaluated at enrolment and after 3 months. AEs, survival, CRP levels, and treatments were also recorded at enrolment and 3 months after enrolment. All exons of UBA1 were sequenced using a next-generation sequencer to determine the variant allele frequencies of pathogenic variants in the peripheral blood of all patients. Results Of the 55 registered patients, 30 patients were confirmed to have pathogenic variants of UBA1. All patients were male, with a median age of 73.5 years. VEXASCAF and CRP levels decreased significantly at 3 months post-enrolment, but the oral prednisolone dose did not change. Only two patients achieved complete remission according to FRENVEX at 3 months after enrolment. During the observation period of 6 months, 28 AEs were observed, including 3 deaths, 4 malignancies from two cases, 2 thromboses, and 13 infections (including 4 mycobacterial infections). Inflammation of the lung and cervical region (i.e. parotid and submandibular gland swelling, tonsillitis, cervical swelling, and pain) were the most common AEs. Conclusions Patients with VEXAS syndrome required high-dose glucocorticoids to achieve remission, and complications—such as malignancy, thrombosis, and infection—occurred frequently within a short observation period.
rheumatology